Results 171 to 180 of about 816,942 (315)

Detection of true pathologic stage I lung cancer in a screening program and the effect on survival [PDF]

, 1981
Myron R. Melamed, Betty J. Flehinger, Muhammad Zaman, Robert T. Heelan, Ellen T. Hallerman, Nael Martini   +5 more
openalex   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Lung cancer screening in Finland: a prospective randomized trial. [PDF]

Acta Oncol
Wichmann V, Iivanainen S, Mattila L, Kokkonen VP, Jartti A, Kurtti A, Kaarteenaho R, Andersen H, Jekunen A, Vasankari T, Koivunen J.   +10 more
europepmc   +1 more source

Screening strategies for cervical cancer and cervical intraepithelial neoplasia [PDF]

, 1981
Ralph M. Richart, Bruce Barron
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Cancer screening adherence among e-cigarette users in the United States. [PDF]

Tob Prev Cessat
Mevawalla A, Khalil M, Rashid Z, Altaf A, Sarfraz A, Pawlik TM.   +5 more
europepmc   +1 more source

Cervical cancer screening: the Pap smear. Summary of an NIH consensus statement. [PDF]

, 1980
Katherine Carson, San Diego, Pelayo Correa, Ellen Flannery, John K. Frost, Ms Genevieve, George B. Hutchison, Raymond H. Kaufman, Duncan Neuhauser, Kenneth L. Noller, E. R. Ramey, Janet L. Williams   +11 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Uptake of cervical cancer screening and its determinants in Africa: Umbrella review. [PDF]

PLoS One
Mengistie BA, Melese M, Gebiru AM, Getnet M, Getahun AB, Tassew WC, Tilahun MM, Bizuneh YB, Negash HK, Baykemagn ND, Asmamaw DB, Yirsaw AN, Abuhay AE, Bitew DA.   +13 more
europepmc   +1 more source

Cancer of the cervix and screening [PDF]

, 1981
Hilary Fernando
openalex   +1 more source